Literature DB >> 9013472

Chronic lymphocytic leukaemia at a county hospital in southern Sweden.

V Hjalmar1, M Carlsson, E Kimby.   

Abstract

We have studied retrospectively patients with chronic lymphocytic leukaemia (CLL), at Ryhov, Jönköping, Sweden during a 10-year-period. This unselected cohort (n = 59) from a well-defined geographical area is suitable for describing the natural course of the disease. The CLL was diagnosed incidentally in the majority of cases. Median-age at diagnosis was 71 years and the male:female ratio was 1.3:1. The diagnosis was based on morphology in 66% and in 33% immunophenotyping specified the diagnosis of B- or T-CLL. At diagnosis 66% were in Rai-stage O/I or Binet-stage A. There were 36% untreated patients and their median-survival was 108 months compared with 84 months for the whole cohort and 72 months for the treated patients. Malignancies were seen in 31% and infections in 83%. Intercurrent diseases played an important role in the survival. During the observation time, only 54% of the deceased patients had died due to the CLL.

Entities:  

Mesh:

Year:  1996        PMID: 9013472     DOI: 10.1007/bf02993859

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.

Authors:  H M Chapel; M Lee
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

Review 3.  B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.

Authors:  G Dighiero; P Travade; S Chevret; P Fenaux; C Chastang; J L Binet
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

4.  Autoimmunity in chronic lymphocytic leukaemia.

Authors:  T J Hamblin; D G Oscier; B J Young
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

Review 5.  Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.

Authors:  M Dicato; H Chapel; H Gamm; M Lee; F Ries; S Marichal; C Wirth; H Griffith; V Brennan
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

6.  Complications and causes of death in B cell chronic lymphocytic leukaemia: a long term study of 105 patients.

Authors:  T I Robertson
Journal:  Aust N Z J Med       Date:  1990-02

7.  Chronic lymphocytic leukemia: a retrospective study of 122 cases.

Authors:  M Erlanson; B Osterman; H Jonsson; P Lenner
Journal:  Eur J Haematol       Date:  1994-02       Impact factor: 2.997

8.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.

Authors:  J L Binet; A Auquier; G Dighiero; C Chastang; H Piguet; J Goasguen; G Vaugier; G Potron; P Colona; F Oberling; M Thomas; G Tchernia; C Jacquillat; P Boivin; C Lesty; M T Duault; M Monconduit; S Belabbes; F Gremy
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

9.  [Severe infections associated with chronic lymphoid leukemia. 159 infectious episodes in 60 patients].

Authors:  P Travade; J D Dusart; M Cavaroc; J Beytout; M Rey
Journal:  Presse Med       Date:  1986-10-11       Impact factor: 1.228

10.  Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.

Authors:  K Ideström; E Kimby; M Björkholm; H Mellstedt; L Engstedt; G Gahrton; B Johansson; D Killander; K H Robérts; A M Stalfelt; A M Udén; B Wadman; S Wählby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11
View more
  1 in total

1.  Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion.

Authors:  M C Lanasa; W A Hogge; C Kubik; J Blancato; E P Hoffman
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.